Slingshot members are tracking this event:

FDA approves Novartis' (NVS) BLA for CAR-T drug candidate CTL019—treating pediatrics, young adults with refractory B-cell acute lymphoblastic leukemia—for Priority Review

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 29, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Acute Lymphoblastic Leukemia, Bla, Fda, Car-t, Ctl019, Priority Review